Lifecore Biomedical, Inc. (LFCR) reports developments as a fully integrated injectables CDMO focused on sterile pharmaceutical products. The company provides development, fill and finish services for syringes, vials and cartridges, including complex formulations, and manufactures injectable-grade hyaluronic acid for biopharmaceutical and biotechnology customers.
Company news commonly covers financial results, revenue and Adjusted EBITDA guidance, commercial site transfer programs, technical transfer and PPQ work, new CDMO manufacturing service agreements, customer program expansions, cost-containment initiatives, biomanufacturing conference participation and Nasdaq inducement equity grants.
Lifecore Biomedical (LFCR) agreed to be acquired by Webster Equity Partners for $6.28 per common share in cash.
The cash price is a 49.5% premium to Lifecore’s September 25 closing price. The transaction is valued at up to $663.7 million if performance milestones are fully met. Common and Series A preferred holders would also receive non-tradable contingent value rights (CVRs). Payments of up to $160 million depend on revenue milestones for 2028 and 2029 and an EBITDA milestone for 2030. Full payment would bring consideration to up to $9.67 per common share or equivalent. Preferred holders would receive their conversion amount in cash at closing.
Closing is expected at the end of the fourth quarter of 2026, subject to stockholder and regulatory approvals and other conditions. Webster has secured financing commitments. A 30-day period permits Lifecore to seek other bids. Lifecore’s common stock would be delisted from Nasdaq after closing.
Lifecore Biomedical (LFCR) will participate in the CPHI Global Conference taking place October 6-8, 2026, in Milan, Italy.
Company leaders, including chief commercial officer Mark DaFonseca and business development directors Mary Evelyn Hudson, Edward Purell, and Dan Dennehy, will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs at booth 8J60. Interested parties are invited to schedule meetings via the provided CDMO email contact.
Lifecore Biomedical (LFCR) signed an agreement to transfer a currently marketed injectable drug product into its CDMO pipeline and support its commercial manufacturing.
The deal, with an unnamed global pharmaceutical company, adds Lifecore’s seventh late-stage commercial program and is the eleventh program added to its pipeline in 2026. The company will perform technical transfer services for a high-viscosity, complex injectable that it describes as strategically important and impactful for patients. Lifecore expects this program to generate commercial revenues in 2028 and states that it is positioned to become one of its largest contracts. With this addition, Lifecore’s late-stage pipeline now contains thirteen programs that could generate commercial revenues by the end of 2028, supporting its strategy of adding high-impact programs and expanding its global customer base.
Lifecore Biomedical (NASDAQ: LFCR) reported second quarter 2026 revenues of $34.2 million, down 6.2% from the comparable prior-year quarter, with gross profit of $12.1 million and a net loss of $6.2 million ($0.19 per diluted share). Adjusted EBITDA* was $8.6 million, compared to $9.1 million a year earlier.
For the first six months of 2026, revenues were $57.4 million, down 19.9% year over year, with gross profit of $16.5 million and a net loss of $21.1 million ($0.61 per diluted share). Adjusted EBITDA* was $9.6 million. Lifecore ended the quarter with about $38.8 million in liquidity, including $17.2 million of cash and $21.6 million of revolver availability, and reaffirmed 2026 guidance for revenues of $120–$125 million and Adjusted EBITDA* of $20.5–$25 million. The company signed six new programs in the quarter, bringing 12‑month additions to 13, including eight late‑stage programs, and advanced more than 40 cost and productivity initiatives.
Lifecore Biomedical (NASDAQ: LFCR) will report financial results for its second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens.
Senior management will host a webcast at 8:00 a.m. Eastern Time, accessible live and on-demand for 30 days via the Investor Events & Presentations page on the company’s website.
Lifecore Biomedical (NASDAQ: LFCR) announced three new customer agreements that expand its pipeline of early- and late-stage CDMO programs across multiple therapeutic and technology areas. All three programs are additive to Lifecore’s high-value pipeline and are expected by the company to contribute to revenue in 2028.
One agreement is a new late-stage regenerative medicine program under which Lifecore will provide technology transfer, engineering support, GMP readiness, and PPQ services, creating near-term development revenue and potential long-term commercial manufacturing. Two additional early-stage agreements with new customers, including a global medical technology company, focus on formulation optimization and development for novel medical technologies.
Lifecore Biomedical (NASDAQ: LFCR) granted an inducement restricted stock unit (RSU) award covering 3,500 shares of common stock on July 13, 2026 under its Equity Inducement Plan. The award was made to a newly hired employee as a material inducement to join the company and was approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment, and are governed by an award agreement and the Inducement Plan.
Lifecore Biomedical (NASDAQ: LFCR) signed a new agreement with a global pharmaceutical company to provide tech transfer and commercial manufacturing services for an injectable suspension product treating neurological disorders.
This becomes Lifecore’s seventh late-stage program agreement in seven months, underscoring growing demand for its high-viscosity and complex drug manufacturing capabilities in the U.S.
Lifecore Biomedical (NASDAQ:LFCR) signed a manufacturing services agreement with a leading ophthalmic disease management company for a next-generation injectable ophthalmic product.
The deal covers process development and tech transfer from vials to pre-filled syringes, adds a sixth late-stage program in seven months, and supports anticipated commercial manufacturing upon regulatory approval.
Lifecore Biomedical (NASDAQ: LFCR) will participate in the William Blair 46th Annual Growth Stock Conference in Chicago. The event runs from June 2-4, 2026 at the Loews Chicago Hotel.
CEO Paul Josephs and CFO Ryan Lake will attend and hold investor meetings.